In clinical trials, intravenous (IV) recombinant tissue-type plasminogen activator (rt-PA) reduces the likelihood of disability if given within 3 hours of acute ischemic stroke. This study compared real-world outcomes between patients treated and patients not treated with IV rt-PA.

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...